ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.822,19
0,14%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202422h01GlobeNewswire Inc.Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
24/05/202413h30GlobeNewswire Inc.BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingNASDAQ:BBIOBridgeBio Pharma Inc
17/05/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
15/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
14/05/202413h30GlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
13/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202413h00GlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
10/04/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
07/04/202419h15GlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
20/03/202412h30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202423h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
06/03/202405h53GlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202423h25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
04/03/202422h17GlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202408h30GlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202422h27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
22/02/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
21/02/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
20/02/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
15/02/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/02/202422h05Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/02/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
07/02/202413h34GlobeNewswire Inc.BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanNASDAQ:BBIOBridgeBio Pharma Inc
06/02/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
05/02/202413h30GlobeNewswire Inc.BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
02/02/202413h00GlobeNewswire Inc.BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Kürzlich von Ihnen besucht

ASX
BASNC
BIT
S29571
Societe Generale Effekten
EU
6407T
6407T
NYSE
KEY-H
NYSE
ROL
Rollins
NASDAQ
FWBBCX
High Income Municipal Mo...
EU
MELE
Melexis
COIN
SPOTCBTC
Cryptospot
AMEX
RISR
FolioBeyond Alternative ...
EU
CMBYX
Credit Mutuel Arkea null
EU
CAFSY
Credit Agricole CIB Fina...
TSXV
PL
USOTC
BPHLY
Bank of the Philippine I... (PK)
TSX
BTCQ
3IQ Bitcoin ETF
AMEX
PXF
Invesco FTSE RAFI Develo...
NASDAQ
AAXRPXX
Barclays Bank PLC Autoca...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten